New aspects of haemophilia treatment : 3rd Symposium, September 21-23, 1995, Copenhagen, Denmark
著者
書誌事項
New aspects of haemophilia treatment : 3rd Symposium, September 21-23, 1995, Copenhagen, Denmark
（Haemostasis : international journal on haemostasis and thrombosis research, v. 26 ; suppl. 1）
Karger, c1996
大学図書館所蔵 件 / 全2件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
内容説明・目次
内容説明
This volume presents the proceedings of the Third Symposium on New Aspects of Haemophilia Treatment, held in Copenhagen in September 1995.
目次
- Part 1 Initiation of haemostasis: cells and the activation of factor VII, L.V.M. Rao and S.I. Rapaport
- monocyte/macrophage regulation of coagulant events, P.B. Tracy et al
- cellular interactions in haemostasis, M. Hoffman et al
- regulation of tissue factor gene expression in human monocytic and endothelial cells, N. Mackman
- the tissue factor - factor VII complex - recent advances towards elucidating the structure and function of the initiator of haemostasis, E.G.D. Tuddenham
- notes on the cell biology of tissue factor, E. Camerer and H. Prydz. Part 2 Regulation of the intiation of haemostasis: influence of the gamma-garboxyglutamic acid-rich domain and hydrophobic stack of factor VIIa on tissue factor binding, E. Persson
- tissue factor interactions - an evaluation using factor VII-factor IX chimeras, J.-Y. Chang
- effect of Ca2+ on the structure and function of factor VIIa, L.C. Peterson and E. Persson
- effect of CA2+ on the structure of vitamin k-dependent coagulation factors, M. Sunnerhagen et al
- computational studies of human prothrombin fragment 1, the Gla domain of factor IX and several biological interesting mutants, L. Li et al. Part 3 Extrinsic coagulation pathway and disease: selectin induction of tissue factor biosynthesis and expression, B. Furie and B.C. Furie
- plasma factor VIIa - measurement and potential clinical significance, J.H. Morrissey
- determinants of coagulation activation in humans, K.A. Bauer et al
- antithrombotic and antilesion benefits without haemorrhagic risks by inhibiting tissue factor pathway, L.A. Harker et al
- role of tissue factor and factor VIIA in the coagulant and inflammatory response to LD100"Escherichia coli" in the baboon, F.B. Taylor, Jr.
- inhibition of tissue factor and cytokine release, E. Gray et al. Part 4 Clinical experience with NovoSeven (rFVIIa): NovoSeven(R)-virus safety, T. Lund Hansen
- long-term follow-up with regard to potential immunogenicity - clinical experience with NovoSeven (recombinant factor VIIa), E.M. Nicolaisen
- dosing and monitoring NovoSeven treatment, U. Hedner
- experience with recombinant factor VIIa in Australia and New Zealand, J. McPherson et al
- major surgery in haemophilic patients with inhibitors using recombinant factor VIIa, J. Ingerslev et al
- NovoSeven compassionate use investigators - recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors, J.M. Lusher
- NovoSeven (recombinant factor VIIa) in central nervous system bleeds, K.M. Rice and G.F. Savidge
- recombinant factor VIIa in joint and muscle bleeding episodes, R. Molskov Bech
- thrombelastgram as a haemostatic monitor during recombinant factor VIIa in haemophilia A patients with inhibitor, A. Yoshioka et al
- American experience with home use of NovoSeven recombinant factor VIIa in haemophiliacs with inhibitors, A.D. Shapiro
- use of recombinant factor VIIa (NovoSeven) in the treatment of two patients affected by type III von (Part contents)
「Nielsen BookData」 より